Last reviewed · How we verify
Extended-release carbamazepine — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Extended-release carbamazepine (Extended-release carbamazepine) — Validus Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Extended-release carbamazepine TARGET | Extended-release carbamazepine | Validus Pharmaceuticals | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Extended-release carbamazepine CI watch — RSS
- Extended-release carbamazepine CI watch — Atom
- Extended-release carbamazepine CI watch — JSON
- Extended-release carbamazepine alone — RSS
Cite this brief
Drug Landscape (2026). Extended-release carbamazepine — Competitive Intelligence Brief. https://druglandscape.com/ci/extended-release-carbamazepine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab